Benign Prostate Hypertrophy (BPH)
Is Fexapotide the Safest and Effective Prostate Cancer Preventative?
That’s what Nymox Pharmaceutical (NYMX) announced in its recent press release stating that results from from 7-year prospective placebo controlled double blind studies of treatment of 995 U.S. men with its lead drug fexapotide were positive.
According to the press release, men who received fexapotide showed a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. The men are enrolled at over . . .